Thanks Neuro. Schering is something of a wildcard lurking under our radar, since with their Org-26576 data in hand for Depression, and soon for ADHD, they'll be making some decisions on the future of those programs. They'll need to decide whether or not to lock up some of Cortex's new low impacts, or risk leaving them hanging out there for a competitor.
Market Data 
Markets 
AI
